Form D · Other
Khiron Life Sciences Corp.
Toronto, A6 · CIK 0001873100
Offering snapshot reported Jun 22, 2022 · SEC filing
- Reported sold
- $955K Offering amount: $955K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 10, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 22, 2022 | Initial | $954,679 | No comparison | 1 | SEC filing |
| Jul 20, 2021 | Initial | $9,887,279 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-449938
Source: Form D, filed Jun 22, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Juan Carlos Echeverry | Director |
| Vicente Fox | Director |
| Joel Friedman | Director, Executive |
| Swapan Kakumanu | Executive |
| Chris Naprawa | Director |
| Deborah Rosati | Director |
| Alvaro Torres | Director, Executive |
| Tejinder Virk | Director, Executive |
| Alvaro Yanez | Director |
Issuer details
Industry: Other (See others in industry)
Address:
100 King Street West Suite 1600
Toronto, A6, M5X 1G5
Toronto, A6, M5X 1G5